- Home
- EDU vs IMVT Comparison
EDU vs IMVT Comparison
Compare EDU & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EDU | IMVT |
|---|---|---|
| Founded | 1993 | 2018 |
| Country | China | United States |
| Employees | 84111 | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 7.3B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | EDU | IMVT |
|---|---|---|
| Price | $46.90 | $38.31 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $62.80 | $33.00 |
| AVG Volume (30 Days) | 411.5K | ★ 1.4M |
| Earning Date | 04-22-2026 | 05-28-2026 |
| Dividend Yield | ★ 2.25% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.83 | N/A |
| Revenue Next Year | $11.16 | N/A |
| P/E Ratio | $24.75 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $41.62 | $14.32 |
| 52 Week High | $64.97 | $39.28 |
Technical Indicators
Market Signals| Indicator | EDU | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 50.60 | 70.12 |
| Support Level | $44.46 | $25.13 |
| Resistance Level | $48.16 | N/A |
| Average True Range (ATR) | 1.17 | 1.36 |
| MACD | 0.45 | 0.17 |
| Stochastic Oscillator | 71.83 | 92.64 |
Price Performance
Historical ComparisonAbout EDU New Oriental Education & Technology Group Inc.
New Oriental Education & Technology is a prominent private education provider in China, offering a wide array of educational services. These include overseas test preparation and consulting services, high school academic tutoring, nonacademic tutoring, and intelligent learning systems and devices. Additionally, the company holds a 57% ownership stake in East Buy, a leading player in the livestreaming e-commerce market.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.